Development of a novel drug targeting delivery system for cervical cancer therapy

Xiao, Li, Ma, Ni, He, Huimin, Li, Jinmei, Cheng, Sinan, Yang, Qian, Hou, Yifan, Song, Fengying, Jin, Huijuan, Su, Xiaorong, Dong, Jing, Zuo, Ruiye, Song, Xigui, Duan, Wei and Hou, Yingchun 2019, Development of a novel drug targeting delivery system for cervical cancer therapy, Nanotechnology, vol. 30, no. 7, pp. 1-16, doi: 10.1088/1361-6528/aaf3f8.

Attached Files
Name Description MIMEType Size Downloads

Title Development of a novel drug targeting delivery system for cervical cancer therapy
Author(s) Xiao, Li
Ma, Ni
He, Huimin
Li, Jinmei
Cheng, Sinan
Yang, Qian
Hou, Yifan
Song, Fengying
Jin, Huijuan
Su, Xiaorong
Dong, Jing
Zuo, Ruiye
Song, Xigui
Duan, WeiORCID iD for Duan, Wei orcid.org/0000-0001-5782-9184
Hou, Yingchun
Journal name Nanotechnology
Volume number 30
Issue number 7
Article ID 075604
Start page 1
End page 16
Total pages 16
Publisher IOP Publishing
Place of publication Bristol, Eng.
Publication date 2019-02-15
ISSN 1361-6528
Keyword(s) cell line, tumor
cell proliferation
cell survival
drug delivery systems
peptides
polyethylene glycols
uterine cervical neoplasms
cervical cancer
targeting peptide
targeted therapy
doxorubicin
microRNA
science & technology
technology
physical sciences
nanoscience & nanotechnology
materials science
physics
Summary 'Targeting peptides' have demonstrated their value in diagnostic imaging and therapy and novel peptide probes specific to cervical cancer were developed. In the M13KE phage dodecapeptide (12-mer) peptide library, the phage clone S7 showed the best binding to the cancer cells as confirmed by immunofluorescence and flow cytometry assays, and was selected for continued studies. Its binding peptide, CSP3, was synthesized from the sequence of S7's 12-mer at the N-terminus of the minor coat protein pIII of this M13KE phage vector. The peptide's binding was analyzed by the same assays used for S7. It was also assessed using competitive inhibition and binding to a tissue chip. The results demonstrated that the CSP3 peptide bound to cervical carcinoma cells with high sensitivity and specificity. The positive results indicated that the peptide CSP3, conjugated with nanomaterials and chemotherapeutics, may be developed as a targeting vehicle for therapeutic drug delivery against cervical cancer, especially cervical cancer with multiple drug resistance. For this aim, we prepared a CSP3 conjugated liposome drug delivery system containing doxorubicin (DOX) and microRNA101 (miR101) expression plasmids (CSP3-Lipo-DOX-miR101), and the primary result showed that the system demonstrated significantly enhanced cytotoxicity to SiHa cells and DOX resistant SiHa cells, SiHa/ADR. Our results showed that CSP3 is a cervical cancer targeting 12aa peptide with high specificity and sensitivity, and the CSP3 conjugated drug delivery system, CSP3-Lipo-DOX-miR101 has promising potential for development as an efficient drug system for the therapy of cervical cancer.
Language eng
DOI 10.1088/1361-6528/aaf3f8
Field of Research MD Multidisciplinary
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, IOP Publishing Ltd
Persistent URL http://hdl.handle.net/10536/DRO/DU:30117241

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 32 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 30 Jan 2019, 14:51:36 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.